Pegfilgrastim
- Generic Name
- Pegfilgrastim
- Brand Names
- Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 208265-92-3
- Unique Ingredient Identifier
- 3A58010674
- Background
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...
- Indication
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...
- Associated Conditions
- Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
- Associated Therapies
- -
An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)
- Conditions
- Interventions
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 53
- Registration Number
- NCT02782845
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT02728531
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT02685111
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT02650973
- Locations
- 🇺🇸
Medpace CPU, Cincinnati, Ohio, United States
🇺🇸WCCT, Cypress, California, United States
🇺🇸Spaulding, West Bend, Wisconsin, United States
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
- Conditions
- Interventions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 406
- Registration Number
- NCT02643420
- Locations
- 🇺🇸
NEA Baptist Clinic | Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States
🇺🇸CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT02531308
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 36
- Registration Number
- NCT02412670
- Locations
- 🇺🇸
Illinois CancerCare-Canton, Canton, Illinois, United States
🇺🇸Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸Illinois CancerCare-Eureka, Eureka, Illinois, United States
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT02392793
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02392039
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT02385851
- Locations
- 🇺🇸
ICON, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.